Lexaria Bioscience (LEXX) said Tuesday that an oral form of tirzepatide processed through its DehydraTECH drug delivery platform caused 47% fewer adverse events than Eli Lilly's (LLY) injectable Zepbound.
The company said partial final results of its study comparing the two versions showed that the oral DehydraTECH-tirzepatide version produced 20 adverse events compared with the injection's 38 adverse events.
Both versions produced "similarly increased levels of insulin from baseline" at the end of the eight-day study of nine participants, while blood glucose reductions from each version were comparable, Lexaria Bioscience added.
Additional results from the study are still undergoing analysis and the company said it plans to add a fifth arm to evaluate DehydraTECH-tirzepatide in an oral capsule.
Shares of Lexaria Bioscience were down more than 11% in early Tuesday trading.
Price: 1.87, Change: -0.19, Percent Change: -9.22
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。